Precise Neoadjuvant Chemoresection of Low Grade NMIBC

NCT06227065 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Bladder Cancer
Non-muscle Invasive Bladder Cancer
Low-risk

Interventions

DRUG: Epirubicin
DRUG: Mitomycin
DRUG: Gemcitabine
DRUG: Docetaxel

Sponsor

University of Bern

Collaborators

[object Object]